Cellular immunotherapy for multiple myeloma

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 3, 2008, Pages 559-577

  Rosenblatt, Jacalyn ^a   Avigan, David ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cellular immunotherapy; dendritic cell vaccines; humoral immunity; multiple myeloma; tumour associated antigens

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CANCER TESTIS ANTIGEN; CD200 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOCHROME P450 1B1; DENDRITIC CELL VACCINE; DEXAMETHASONE; GAMMA INTERFERON; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6 ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; M PROTEIN; MAPATUMUMAB; MELPHALAN; MONOCLONAL ANTIBODY; MUCIN 1; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CALCIUM BLOOD LEVEL; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CD4+ T LYMPHOCYTE; CELL FUSION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EFFECTOR CELL; FEVER; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFER; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TARGET CELL; TREATMENT OUTCOME; TUMOR IMMUNITY;

CANCER VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE TRANSFUSION; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 51349132422     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.07.007     Document Type: Review

References (120)

1. Bataille R., and Harousseau J.L. Multiple myeloma. The New England Journal of Medicine 336 (1997) 1657-1664
2. Rajkumar S.V., and Greipp P.R. Prognostic factors in multiple myeloma. Hematology/Oncology Clinics of North America 13 (1999) 1295-1314 xi
3. Greipp P.R. Prognosis in myeloma. Mayo Clinic Proceedings 69 (1994) 895-902
4. Durie B.G., and Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36 (1975) 842-854
5. Dewald G.W., Kyle R.A., Hicks G.A., et al. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66 (1985) 380-390
6. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. Journal of Clinical Oncology 23 (2005) 3412-3420
7. Alexanian R., and Dimopoulos M. The treatment of multiple myeloma. The New England Journal of Medicine 330 (1994) 484-489
8. Jagannath S., and Barlogie B. Autologous bone marrow transplantation for multiple myeloma. Hematology/Oncology Clinics of North America 6 (1992) 437-449
9. Harousseau J.L., Milpied N., Jouet J.P., et al. Intensive therapy for high grade multiple myeloma (MM). Bone Marrow Transplantation 7 Suppl. 2 (1991) 28
10. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. The New England Journal of Medicine 335 (1996) 91-97
11. Kyle R.A., and Rajkumar S.V. Multiple myeloma. The New England Journal of Medicine 351 (2004) 1860-1873
12. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine 352 (2005) 2487-2498
13. Barlogie B., Shaughnessy J., Tricot G., et al. Treatment of multiple myeloma. Blood 103 (2004) 20-32
14. Weiden P.L., Sullivan K.M., Flournoy N., et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. The New England Journal of Medicine 304 (1981) 1529-1533
15. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 (1995) 2041-2050
16. Gahrton G., Tura S., Ljungman P., et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. Journal of Clinical Oncology 13 (1995) 1312-1322
17. Gahrton G., Svensson H., Cavo M., et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. British Journal of Haematology 113 (2001) 209-216
18. Gahrton G., Tura S., Ljungman P., et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. The New England Journal of Medicine 325 (1991) 1267-1273
19. Crawley C., Iacobelli S., Bjorkstrand B., et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109 (2007) 3588-3594
20. Bensinger W.I., Buckner C.D., Anasetti C., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88 (1996) 2787-2793
21. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. Journal of Clinical Oncology 17 (1999) 208-215
22. Martinelli G., Terragna C., Zamagni E., et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. Journal of Clinical Oncology 18 (2000) 2273-2281
23. Harrison S.J., and Cook G. Immunotherapy in multiple myeloma - possibility or probability?. British Journal of Haematology 130 (2005) 344-362
24. Tricot G., Vesole D.H., Jagannath S., et al. Graft-versus-myeloma effect: proof of principle. Blood 87 (1996) 1196-1198
25. Zeiser R., Bertz H., Spyridonidis A., et al. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplantation 34 (2004) 923-928
26. Verdonck L.F., Lokhorst H.M., Dekker A.W., et al. Graft-versus-myeloma effect in two cases. Lancet 347 (1996) 800-801
27. Bertz H., Burger J.A., Kunzmann R., et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 11 (1997) 281-283
28. Lokhorst H.M., Schattenberg A., Cornelissen J.J., et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Journal of Clinical Oncology 18 (2000) 3031-3037
29. van de Donk N.W., Kroger N., Hegenbart U., et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplantation 37 (2006) 1135-1141
30. Bjorkstrand B.B., Ljungman P., Svensson H., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88 (1996) 4711-4718
31. Alyea E., Weller E., Schlossman R., et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 98 (2001) 934-939
32. Kroger N., Sayer H.G., Schwerdtfeger R., et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 100 (2002) 3919-3924
33. Mohty M., Kuentz M., Michallet M., et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 100 (2002) 3128-3134
34. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 (2003) 3447-3454
35. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 (2006) 3474-3480
36. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. The New England Journal of Medicine 356 (2007) 1110-1120
37. Orsini E., Alyea E.P., Schlossman R., et al. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplantation 25 (2000) 623-632
38. Banerjee D.K., Dhodapkar M.V., Matayeva E., et al. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108 (2006) 2655-2661
39. Takahashi T., Makiguchi Y., Hinoda Y., et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. Journal of Immunology 153 (1994) 2102-2109
40. Brossart P., Schneider A., Dill P., et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Research 61 (2001) 6846-6850
41. Lim S.H., Wang Z., Chiriva-Internati M., et al. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 97 (2001) 1508-1510
42. Szmania S., Tricot G., and van Rhee F. NY-ESO-1 immunotherapy for multiple myeloma. Leukemia & Lymphoma 47 (2006) 2037-2048
43. Atanackovic D., Arfsten J., Cao Y., et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 109 (2007) 1103-1112
44. Batchu R.B., Moreno A.M., Szmania S.M., et al. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Research 65 (2005) 10041-10049
45. Hundemer M., Schmidt S., Condomines M., et al. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Experimental Hematology 34 (2006) 486-496
46. Chiriva-Internati M., Ferraro R., Prabhakar M., et al. The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma. Journal of Translational Medicine 6 (2008) 15
47. Beckhove P., Schutz F., Diel I.J., et al. Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. International Journal of Cancer 105 (2003) 444-453
48. Yi Q., Osterborg A., Bergenbrant S., et al. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86 (1995) 3043-3049
49. van Rhee F., Szmania S.M., Zhan F., et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105 (2005) 3939-3944
50. Goodyear O., Piper K., Khan N., et al. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 106 (2005) 4217-4224
51. Maxwell C.A., Rasmussen E., Zhan F., et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 104 (2004) 1151-1158
52. Crainie M., Belch A.R., Mant M.J., et al. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood 93 (1999) 1684-1696
53. Chen J., Schmitt A., Bunjes D., et al. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation. International Journal of Oncology 30 (2007) 1119-1127
54. Schmitt M., Schmitt A., Rojewski M.T., et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111 (2008) 1357-1365
55. Bergmann L., Miething C., Maurer U., et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90 (1997) 1217-1225
56. Sugiyama H. Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia. Leukemia & Lymphoma 30 (1998) 55-61
57. Oka Y., Tsuboi A., Taguchi T., et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 13885-13890
58. Tsuboi A., Oka Y., Nakajima H., et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. International Journal of Hematology 86 (2007) 414-417
59. Lynch R.G., Graff R.J., Sirisinha S., et al. Myeloma proteins as tumor-specific transplantation antigens. Proceedings of the National Academy of Sciences of the United States of America 69 (1972) 1540-1544
60. Houet L., and Veelken H. Active immunotherapy of multiple myeloma. European Journal of Cancer 42 (2006) 1653-1660
61. Moshitzky S., Kukulansky T., Haimovich J., et al. Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin. Immunology and Cell Biology 86 (2008) 261-267
62. Lauritzsen G.F., Weiss S., Dembic Z., et al. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 5700-5704
63. Yi Q. Dendritic cell-based immunotherapy in multiple myeloma. Leukemia & Lymphoma 44 (2003) 2031-2038
64. Yi Q., Eriksson I., He W., et al. Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. British Journal of Haematology 96 (1997) 338-345
65. Dabadghao S., Bergenbrant S., Anton D., et al. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. British Journal of Haematology 100 (1998) 647-654
66. Wen Y.J., Barlogie B., and Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 97 (2001) 1750-1755
67. Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. European Journal of Immunology 26 (1996) 2671-2679
68. Bogen B., Ruffini P.A., Corthay A., et al. Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica 91 (2006) 941-948
69. Bergenbrant S., Yi Q., Osterborg A., et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. British Journal of Haematology 92 (1996) 840-846
70. Osterborg A., Yi Q., Henriksson L., et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 91 (1998) 2459-2466
71. Rasmussen T., Hansson L., Osterborg A., et al. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 101 (2003) 4607-4610
72. Coscia M., Mariani S., Battaglio S., et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 18 (2004) 139-145
73. Kwak L.W., Taub D.D., Duffey P.L., et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345 (1995) 1016-1020
74. Li Y., Bendandi M., Deng Y., et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood 96 (2000) 2828-2833
75. Neelapu S.S., Munshi N.C., Jagannath S., et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplantation 36 (2005) 315-323
76. Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Reviews 13 (1999) 51-64
77. Hayashi T., Hideshima T., Akiyama M., et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 102 (2003) 1435-1442
78. Wen Y.J., Ling M., Bailey-Wood R., et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clinical Cancer Research 4 (1998) 957-962
79. Lim S.H., and Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. International Journal of Cancer 83 (1999) 215-222
80. Cull G., Durrant L., Stainer C., et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. British Journal of Haematology 107 (1999) 648-655
81. Titzer S., Christensen O., Manzke O., et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. British Journal of Haematology 108 (2000) 805-816
82. Reichardt V.L., Okada C.Y., Liso A., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 93 (1999) 2411-2419
83. Liso A., Stockerl-Goldstein K.E., Auffermann-Gretzinger S., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biology Blood Marrow Transplantation 6 (2000) 621-627
84. Reichardt V.L., Milazzo C., Brugger W., et al. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica 88 (2003) 1139-1149
85. Bendandi M., Rodriguez-Calvillo M., Inoges S., et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia & Lymphoma 47 (2006) 29-37
86. Lee J.J., Choi B.H., Kang H.K., et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leukemia & Lymphoma 48 (2007) 2022-2031
87. Vasir B., Borges V., Wu Z., et al. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. British Journal of Haematology 129 (2005) 687-700
88. Gong J., Chen D., Kashiwaba M., et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Medicine 3 (1997) 558-561
89. Gong J., Chen D., Kashiwaba M., et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 6279-6283
90. Gong J., Koido S., Chen D., et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99 (2002) 2512-2517
91. Hao S., Bi X., Xu S., et al. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Experimental Oncology 26 (2004) 300-306
92. Walewska R., Teobald I., Dunnion D., et al. Preclinical development of hybrid cell vaccines for multiple myeloma. European Journal of Haematology 78 (2007) 11-20
93. Baecher-Allan C., Brown J.A., Freeman G.J., et al. CD4+ CD25high regulatory cells in human peripheral blood. Journal of Immunology 167 (2001) 1245-1253
94. Dieckmann D., Plottner H., Berchtold S., et al. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. The Journal of Experimental Medicine 193 (2001) 1303-1310
95. Jonuleit H., Schmitt E., Stassen M., et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. The Journal of Experimental Medicine 193 (2001) 1285-1294
96. Beyer M., Kochanek M., Giese T., et al. In vivo peripheral expansion of naive CD4+ CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 107 (2006) 3940-3949
97. Prabhala R.H., Neri P., Bae J.E., et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 107 (2006) 301-304
98. Onizuka S., Tawara I., Shimizu J., et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Research 59 (1999) 3128-3133
99. Javia L.R., and Rosenberg S.A. CD4+ CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. Journal of Immunotherapy 26 (2003) 85-93
100. Prasad S.J., Farrand K.J., Matthews S.A., et al. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+ CD25+ regulatory T cells. Journal of Immunology 174 (2005) 90-98
101. Rapoport A.P., Stadtmauer E.A., Aqui N., et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nature Medicine 11 (2005) 1230-1237
102. Ferlazzo G., and Munz C. NK cell compartments and their activation by dendritic cells. Journal of Immunology 172 (2004) 1333-1339
103. Zheng C., Ostad M., Andersson M., et al. Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma. British Journal of Haematology 118 (2002) 778-785
104. Frohn C., Hoppner M., Schlenke P., et al. Anti-myeloma activity of natural killer lymphocytes. British Journal of Haematology 119 (2002) 660-664
105. Alici E., Konstantinidis K.V., Sutlu T., et al. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Experimental Hematology 35 (2007) 1839-1846
106. Alici E., Sutlu T., Bjorkstrand B., et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 111 (2008) 3155-3162
107. Chatterjee M., Chakraborty T., and Tassone P. Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. European Journal of Cancer 42 (2006) 1640-1652
108. Klein B., Zhang X.G., Jourdan M., et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73 (1989) 517-526
109. Zhang X.G., Klein B., and Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 74 (1989) 11-13
110. Vink A., Coulie P., Warnier G., et al. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. The Journal of Experimental Medicine 172 (1990) 997-1000
111. Bataille R., Barlogie B., Lu Z.Y., et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86 (1995) 685-691
112. van Zaanen H.C., Koopmans R.P., Aarden L.A., et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. The Journal of Clinical Investigation 98 (1996) 1441-1448
113. van Zaanen H.C., Lokhorst H.M., Aarden L.A., et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. British Journal of Haematology 102 (1998) 783-790
114. Klein B., Wijdenes J., Zhang X.G., et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78 (1991) 1198-1204
115. Moreau P., Harousseau J.L., Wijdenes J., et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. British Journal of Haematology 109 (2000) 661-664
116. 2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplantation 36 (2005) 771-779
117. Stevenson F.K., Bell A.J., Cusack R., et al. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 77 (1991) 1071-1079
118. Kretz-Rommel A., Qin F., Dakappagari N., et al. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. Journal of Immunology 180 (2008) 699-705
119. Tai Y.T., Catley L.P., Mitsiades C.S., et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Research 64 (2004) 2846-2852
120. Tai Y.T., Li X., Tong X., et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Research 65 (2005) 5898-5906